Today: 27 June 2026
RTX Stock Just Got Downgraded After an 11% Slide. The Earnings Beat Wasn’t Enough
27 April 2026
2 mins read

RTX Stock Just Got Downgraded After an 11% Slide. The Earnings Beat Wasn’t Enough

New York, April 27, 2026, 12:03 EDT

  • RTX hovered around $174 in late-morning New York trading, following a downgrade to “hold” from “buy” by Erste Group.
  • RTX snapped a five-day slide, despite topping first-quarter estimates and bumping up its 2026 outlook.
  • Shares remain under pressure, weighed down by tariff costs, valuation concerns, and a wider pullback across defense stocks.

RTX didn’t recover much ground Monday, staying under pressure after Erste Group Bank cut its rating to “hold” from “buy.” That move followed last week’s steep drop. Shares hovered near $174.16, barely budging, trading between $173.10 and $176.95 during the session. Finviz

The timing of the downgrade is notable—coming just days after RTX posted results that typically reassure defense investors: sales and profits up, and management lifting its full-year outlook. But the market isn’t buying it this time. There’s fresh skepticism about whether stronger demand for missiles, jet engines and maintenance will be enough to counter higher tariffs and a stock price that had already sprinted ahead until the recent retreat.

RTX dropped 11.3% in just five sessions, according to Trefis, erasing roughly $30 billion in market cap. The S&P 500, meanwhile, edged up 0.5%. That puts RTX’s valuation close to $235 billion. The market, for now, isn’t rewarding a beat-and-raise quarter.

Erste downgraded RTX to “hold,” according to MarketBeat, after having only started coverage at “buy” back on March 24, Finviz data showed Monday. Despite the shift, MarketBeat’s tally still reflects a “Moderate Buy” consensus overall: 13 analysts rate it buy, with seven holds, one strong buy, and just one sell recommendation. MarketBeat

RTX posted first-quarter sales of $22.1 billion, climbing 9% from last year. Adjusted earnings per share came in at $1.78, marking a 21% increase. That adjusted EPS figure strips out some acquisition and accounting impacts. For 2026, the company bumped up its adjusted sales target to a range of $92.5 billion to $93.5 billion and sees adjusted EPS landing between $6.70 and $6.90.

Chris Calio, chairman and CEO, described the quarter as a “very strong start” to 2026, highlighting “strength … in our defense business” after RTX lifted its outlook. The company’s backlog landed at $271 billion: $162 billion in commercial, $109 billion in defense. RTX

Portfolio results landed in positive territory this quarter. Raytheon’s top line climbed 10%, bolstered by solid demand for its land and air defense platforms like Patriot and GEM-T missiles. Pratt & Whitney posted an 11% revenue increase, driven in part by a 19% jump in commercial aftermarket sales—mainly parts and repair after aircraft are in operation. Collins Aerospace turned in 5% sales growth.

Tariffs are still a pressing concern. Chief Financial Officer Neil Mitchill told analysts there’s “no change today” regarding RTX’s tariff stance. So far, the company has paid around $500 million in tariffs under the International Emergency Economic Powers Act. Mitchill said they’ll pursue refunds as the process comes into focus. RTX hasn’t recognized any income tied to potential reversals, and those possible refunds aren’t reflected in current guidance. Investing.com

RTX’s numbers and outlook continue to back the fundamentals, according to Traders Union’s Viktoras Karapetjanc, but short-term momentum hasn’t turned around. Karapetjanc previously pointed to $177.60 as a key support—if shares held there, a “stabilize and potentially rebound” scenario was possible. By late Monday morning, though, the stock had dipped under that mark. Traders Union

It’s not just RTX feeling the squeeze. Northrop Grumman dropped 5% last week, despite posting stronger first-quarter revenue. The company left its 2026 sales outlook untouched, a contrast to RTX, which had just bumped its own forecast, as Reuters pointed out.

Despite surging weapons demand, defense names haven’t kept up. Lockheed Martin, Northrop, RTX, General Dynamics, and L3Harris are all trading well below highs reached in the aftermath of the Iran-war headlines, Barron’s notes. The issue: much of the anticipated boost from increased defense spending may already be reflected in the shares.

RTX doesn’t have to prove demand—it’s there. The bigger concern: Can it actually convert that backlog into cash quickly and without hiccups? With tariffs, pricier engines, and rotation across the sector making buyers think twice, that’s what will test the valuation.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • Telix Pharmaceuticals and Two Australian Insider-Led Growth Stocks Highlighted
    June 27, 2026, 11:07 AM EDT. Telix Pharmaceuticals (ASX:TLX), a A$5.2 billion biopharmaceutical firm specializing in radiopharmaceuticals for cancer imaging and treatment, draws growth-focused investors despite ongoing losses. The company reported US$621.9 million revenue from Precision Medicine and relies heavily on its oncology pipeline with products like Illuccix and late-stage candidates TLX591 and TLX101. Key risks include high R&D costs, regulatory scrutiny, pricing pressures, and trial dependencies. Also featured are two Australian insider-led growth stocks identified by the Fast Growing Stocks With High Insider Ownership screener, highlighting firms with aligned management-shareholder interests amid mixed inflation and cautious central bank policies.

Latest articles

Generate Biomedicines stock ends week back above IPO price as volume jumps

Generate Biomedicines stock ends week back above IPO price as volume jumps

27 June 2026
Generate Biomedicines (NASDAQ:GENB) surged 13.7% since June 18 to close Friday at $16.47—above its $16 IPO price—with heavy volume and a $2.11B market cap, as investors weigh its $516.6M cash pile, ongoing clinical trial risks, and lack of product revenue, while sector momentum lifts biotech stocks.
Snowflake (NYSE:SNOW) finishes up for the week after Russell rebalance trading

Snowflake (NYSE:SNOW) finishes up for the week after Russell rebalance trading

27 June 2026
Snowflake Inc (NYSE:SNOW) surged 9.65% to $248.96 on Friday with trading volume five times the weekly average, driven by FTSE Russell’s U.S. index reconstitution, turning a negative week into a 7.2% gain since June 18, as investors await whether the stock can hold above its previous $225.95–$230.41 range when index-driven liquidity fades next week.
GameStop (NYSE:GME) holds close to cash levels after company guides for $600 million in EBITDA

GameStop (NYSE:GME) holds close to cash levels after company guides for $600 million in EBITDA

27 June 2026
GameStop surged 3.57% to $21.76 and jumped after hours as it forecast FY2026 adjusted EBITDA above $600 million, nearly doubling from 2025; with a $9.76 billion market cap now close to its $9.7 billion in cash, securities, digital assets, and collateral, investors are weighing whether GameStop’s cash-rich balance sheet can support equity while Ryan Cohen pursues an eBay bid.
ImmunityBio (NASDAQ:IBRX) trades after post-Russell spike with 46% more volume

ImmunityBio (NASDAQ:IBRX) trades after post-Russell spike with 46% more volume

27 June 2026
ImmunityBio surged 11.8% to $8.71 on Friday with volume tripling its average, as Russell index reconstitution took effect; Monday’s trading will reveal if demand persists or if the spike was driven by index flows, with no imminent company events and recent insider selling accounting for just 0.06% of Friday’s volume.
Atomera Stock Jumps Nearly 50% After Synopsys Deal Puts GaN Chip Tech in Focus
Previous Story

Atomera Stock Jumps Nearly 50% After Synopsys Deal Puts GaN Chip Tech in Focus

Dow Jones Today: Oil Spike, Fed Week and Big Tech Earnings Put Rally on Edge
Next Story

Dow Jones Today: Oil Spike, Fed Week and Big Tech Earnings Put Rally on Edge

Go toTop